Number | Relative risk | 95%CI lower limit | 95%CI upper limit | p value | Overall p value | |
---|---|---|---|---|---|---|
Chronic GVHD | ||||||
Rituximab dose (mg/m2) | ||||||
<1000 | 208 | 1 | 0.03 | |||
1000–1999 | 110 | 0.64 | 0.46 | 0.90 | 0.01 | |
2000–3375 | 46 | 0.92 | 0.62 | 1.36 | 0.67 | |
Non-relapse mortality | ||||||
Rituximab dose (mg/m2) | ||||||
<1000 | 208 | 1 | 0.06 | |||
1000–1999 | 109 | 0.90 | 0.54 | 1.51 | 0.70 | |
2000–3375 | 45 | 0.18 | 0.04 | 0.75 | 0.02 | |
Progression/relapse | ||||||
Rituximab dose (mg/m2) | ||||||
<1000 | 208 | 1 | 0.90 | |||
1000–1999 | 109 | 1.01 | 0.63 | 1.61 | 0.97 | |
2000–3375 | 45 | 0.85 | 0.40 | 1.78 | 0.66 | |
PFS | ||||||
Rituximab dose (mg/m2) | ||||||
<1000 | 208 | 1 | 0.21 | |||
1000–1999 | 109 | 0.99 | 0.70 | 1.39 | 0.94 | |
2000–3375 | 45 | 0.56 | 0.30 | 1.07 | 0.08 | |
Mortality | ||||||
Rituximab dose (mg/m2) | ||||||
<1000 | 214 | 1 | 0.052 | |||
1000–1999 | 113 | 1.10 | 0.76 | 1.59 | 0.63 | |
2000–3375 | 47 | 0.43 | 0.21 | 0.90 | 0.02 |